ADMA Biologics Inc (ADMA) - Total Liabilities
Based on the latest financial reports, ADMA Biologics Inc (ADMA) has total liabilities worth $274.86 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ADMA Biologics Inc equity growth rate to track the company's year-over-year net asset growth rate.
ADMA Biologics Inc - Total Liabilities Trend (2006–2025)
This chart illustrates how ADMA Biologics Inc's total liabilities have evolved over time, based on quarterly financial data. See ADMA cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
ADMA Biologics Inc Competitors by Total Liabilities
The table below lists competitors of ADMA Biologics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sichuan Expressway Co Ltd
SHG:601107
|
China | CN¥45.54 Billion |
|
Emami Limited
NSE:EMAMILTD
|
India | Rs9.14 Billion |
|
Newell Rubbermaid Inc.
NASDAQ:NWL
|
USA | $8.32 Billion |
|
Intapp Inc
NASDAQ:INTA
|
USA | $384.93 Million |
|
Ziraat Gayrimenkul Yatirim Ortakligi AS
IS:ZRGYO
|
Turkey | TL11.13 Billion |
|
Xiamen Port Development Co Ltd
SHE:000905
|
China | CN¥12.42 Billion |
|
eClerx Services Limited
NSE:ECLERX
|
India | Rs11.33 Billion |
|
Jiamei Food Packaging Chuzhou Co
SHE:002969
|
China | CN¥1.13 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down ADMA Biologics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ADMA Biologics Inc (ADMA) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ADMA Biologics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ADMA Biologics Inc (2006–2025)
The table below shows the annual total liabilities of ADMA Biologics Inc from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $146.92 Million | +5.20% |
| 2024-12-31 | $139.66 Million | -28.00% |
| 2023-12-31 | $193.98 Million | -1.28% |
| 2022-12-31 | $196.49 Million | +45.46% |
| 2021-12-31 | $135.08 Million | +13.11% |
| 2020-12-31 | $119.42 Million | +18.36% |
| 2019-12-31 | $100.90 Million | +46.00% |
| 2018-12-31 | $69.11 Million | +2.10% |
| 2017-12-31 | $67.69 Million | +140.51% |
| 2016-12-31 | $28.14 Million | +22.93% |
| 2015-12-31 | $22.89 Million | +7.89% |
| 2014-12-31 | $21.22 Million | +103.90% |
| 2013-12-31 | $10.41 Million | +69.72% |
| 2012-12-31 | $6.13 Million | +115461.12% |
| 2011-12-31 | $5.31K | -57.06% |
| 2010-12-31 | $12.36K | -99.86% |
| 2009-12-31 | $8.69 Million | +228.22% |
| 2008-12-31 | $2.65 Million | -81.93% |
| 2007-12-31 | $14.65 Million | 0.00% |
| 2006-12-31 | $14.65 Million | -- |
About ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indic… Read more